Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

Overview of attention for article published in BMC Cancer, March 2014

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 1 X post from an account with 75 followers.

NET. Octreotide, metronomic capecitabine and bevacizumab in well/moderately differentiated NET: http://t.co/3EpWjbN9Zv

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.